A Phase I First|in|Human Study of ABBV|011

A Phase 1 First in Human Study Evaluating Safety, Pharmacokinetics and Efficacy of ABBV-400 as Monotherapy and in Combination With Bevacizumab in Adult Subjects ...

MA09.09 First-In-Human Phase 1 Study of ABBV-399, an Antibody ...

First-In-Human Phase 1 Study of ABBV-. 399, an Antibody-Drug Conjugate (ADC). Targeting C-Met, in Patients with Non-. Small Cell Lung Cancer (NSCLC). Eric ...

Paper: A First-in-Human Phase 1 Study of ABBV-525, a ... - Abstract

3101 A First-in-Human Phase 1 Study of ABBV-525, a Small-Molecule MALT1 Inhibitor, in Patients with Relapsed or Refractory B-Cell Non-Hodgkin ...

Budigalimab Plus ABBV-151 Demonstrates Variable Activity Across ...

The first-in-human, open-label, multicenter study consisted of a dose-escalation phase by Bayesian optimal interval design (part 1) and a dose- ...

AbbVie to Acquire ImmunoGen, including its Flagship Cancer ...

Proposed acquisition will accelerate AbbVie's entry into the commercial market for ovarian cancer; ELAHERE® is a first-in-class ...

A Phase 1 First-in-Human Study with ABBV-155 Alone and in ...

ABBV-155 with a taxane (paclitaxel or docetaxel) combination cohort will enroll participants with R/R non-small cell lung cancer (NSCLC) and ...

Aura Biosciences Announces First Patient Dosed in Phase 1 Study ...

Aura Biosciences Announces Interim Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (AU-011) for the ...

Search for a clinical trial - Orphanet

First-in-Human Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of the BTK Degrader, ABBV-101, in Participants With B-cell Malignancies ...

AbbVie Drug Expected to Rival Bristol Myers's New Schizophrenia ...

The preliminary results announced Monday are from two placebo-controlled Phase 2 studies designed to evaluate multiple doses of emraclidine, a ...

A Phase 1b Study of Telisotuzumab Vedotin in Combination With ...

Clinical results from an ongoing first-in-human phase 1-1b study evaluating Teliso-V monotherapy in advanced NSCLC revealed a favorable ...

ASCO 2024 preview – jury still out on AbbVie's cancer push

... first-in-human data at the conference, not ... a phase 1 trial, suggest that ABBV-706 is indeed an improvement. ... The study will also ...

A Phase I First-in-Human Study of ABBV-383, a B-Cell Maturation ...

CONCLUSIONABBV-383 in patients with RRMM was well tolerated with an ORR of 68% at doses ≥ 40 mg. This novel therapy's promising preliminary ...

A Phase I First-in-Human Study of ABBV-383, a B-Cell Maturation ...

PURPOSE ABBV-383, a B-cell maturation antigen × CD3 T-cell engaging bispecific antibody, has demonstrated promising results in an ongoing first-in-human ...

NCT03639194 - Cancer Trial Results

A Phase I First-in-Human Study of ABBV-011, a Seizure-Related Homolog Protein 6-Targeting Antibody-Drug Conjugate, in Patients With Small Cell Lung Cancer.

Clinical Studies in Ki-CONNECT Recruiting - 京都大学

First-in-Human Study to Evaluate the Safety ... [M23-385]A Phase 1 study of ABBV-706 alone or in ... NCCH2101/MK011 trial (Perfume trial), Department ...

A first-in-human, phase 1, dose-escalation study of ABBV-176, an ...

This phase 1, dose-escalation study (NCT03145909) evaluated the safety, pharmacokinetics, and preliminary activity of ABBV-176 in patients with ...

Aura Biosciences Announces Dosing of First Patient in Phase 2 ...

Aura Biosciences Announces Dosing of First Patient in Phase 2 Study Evaluating Suprachoroidal Administration of AU-011 in Patients with Choroidal Melanoma.

臨床研究等提出・公開システム - jRCT

[M17-327] A Phase I Study of ABBV-011 as a Single-Agent and in Combination With Budigalimab (ABBV-181) in Subjects With Relapsed or Refractory Small Cell Lung ...

Pipeline - AbbVie Science

A first-in-human phase 1 study of ABBV-319, an antibody-drug conjugate composed of a CD19 antibody linked to a potent propriety glucocorticosteroid, in patients ...

First-in-Human Phase I Study of ABBV-085, an Antibody-Drug ...

ABBV-085 is a monomethyl auristatin-E antibody-drug conjugate that targets LRRC15 and showed antineoplastic efficacy in preclinical experiments. Herein, we ...